Urogen Pharma (NASDAQ:URGN) Insider Sells $16,644.81 in Stock

Key Points

• Mark Schoenberg, an insider at Urogen Pharma, sold 871 shares on September 8th at an average price of $19.11, decreasing his position by 0.58% and leaving him with 149,025 shares valued at approximately $2.85 million.
• Urogen Pharma reported a quarterly EPS loss of ($1.05), missing analyst estimates; however, it achieved revenues of $24.22 million, slightly above expectations.
• Institutional ownership of Urogen Pharma stands at 91.29%, with several investors recently increasing their stakes, including Osaic Holdings and Squarepoint Ops, which boosted their holdings significantly in the second quarter.

Urogen Pharma (NASDAQ:URGN - Get Free Report) insider Mark Schoenberg sold 871 shares of the stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $19.11, for a total value of $16,644.81. Following the transaction, the insider owned 149,025 shares of the company's stock, valued at approximately $2,847,867.75. The trade was a 0.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Mark Schoenberg also recently made the following trade(s):

• On Monday, August 11th, Mark Schoenberg sold 10,000 shares of Urogen Pharma stock. The stock was sold at an average price of $17.69, for a total value of $176,900.00.
• On Monday, July 28th, Mark Schoenberg sold 5,149 shares of Urogen Pharma stock. The shares were sold at an average price of $19.14, for a total value of $98,551.86.

Urogen Pharma Price Performance

URGN stock traded down $0.46 during mid-day trading on Friday, reaching $18.79. The company had a trading volume of 886,418 shares, compared to its average volume of 1,085,832. The stock has a 50 day simple moving average of $18.19 and a two-hundred day simple moving average of $12.90. The company has a market capitalization of $869.23 million, a price-to-earnings ratio of -5.66 and a beta of 1.10. Urogen Pharma has a 52 week low of $3.42 and a 52 week high of $21.71.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($1.05) earnings per share for the quarter, missing analysts' consensus estimates of ($0.82) by ($0.23). The company had revenue of $24.22 million during the quarter, compared to the consensus estimate of $23.06 million. Urogen Pharma had a negative net margin of 164.44% and a negative return on equity of 97,487.15%. On average, equities analysts predict that Urogen Pharma will post -3.12 EPS for the current year.

Analyst Upgrades and Downgrades

URGN has been the topic of a number of research reports. Wall Street Zen upgraded Urogen Pharma from a "sell" rating to a "hold" rating in a research report on Saturday. HC Wainwright cut their target price on Urogen Pharma from $50.00 to $40.00 and set a "buy" rating on the stock in a research report on Monday, August 11th. Piper Sandler started coverage on Urogen Pharma in a research report on Monday, August 18th. They set an "overweight" rating and a $36.00 target price on the stock. The Goldman Sachs Group set a $16.00 price target on Urogen Pharma and gave the stock a "neutral" rating in a research note on Friday, June 13th. Finally, Scotiabank reaffirmed an "outperform" rating on shares of Urogen Pharma in a research note on Friday, June 13th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $32.00.

Institutional Trading of Urogen Pharma

A number of institutional investors and hedge funds have recently modified their holdings of URGN. Osaic Holdings Inc. increased its position in shares of Urogen Pharma by 491.2% during the second quarter. Osaic Holdings Inc. now owns 3,695 shares of the company's stock valued at $50,000 after acquiring an additional 3,070 shares during the last quarter. CWM LLC increased its position in shares of Urogen Pharma by 6,047.1% during the first quarter. CWM LLC now owns 5,225 shares of the company's stock valued at $58,000 after acquiring an additional 5,140 shares during the last quarter. Lazard Asset Management LLC purchased a new stake in shares of Urogen Pharma during the fourth quarter valued at approximately $67,000. GAMMA Investing LLC increased its position in shares of Urogen Pharma by 6,908.4% during the first quarter. GAMMA Investing LLC now owns 7,499 shares of the company's stock valued at $83,000 after acquiring an additional 7,392 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its position in shares of Urogen Pharma by 422.0% during the second quarter. Tower Research Capital LLC TRC now owns 6,891 shares of the company's stock valued at $94,000 after acquiring an additional 5,571 shares during the last quarter. 91.29% of the stock is owned by hedge funds and other institutional investors.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.